HomeComparePCTGY vs ABBV

PCTGY vs ABBV: Dividend Comparison 2026

PCTGY yields 31.40% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PCTGY wins by $41.1K in total portfolio value
10 years
PCTGY
PCTGY
● Live price
31.40%
Share price
$6.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$143.4K
Annual income
$19,741.77
Full PCTGY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PCTGY vs ABBV

📍 PCTGY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCTGYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCTGY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCTGY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCTGY
Annual income on $10K today (after 15% tax)
$2,668.76/yr
After 10yr DRIP, annual income (after tax)
$16,780.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $4,275.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCTGY + ABBV for your $10,000?

PCTGY: 50%ABBV: 50%
100% ABBV50/50100% PCTGY
Portfolio after 10yr
$122.9K
Annual income
$22,256.77/yr
Blended yield
18.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PCTGY
No analyst data
Altman Z
2.4
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCTGY buys
0
ABBV buys
0
No recent congressional trades found for PCTGY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCTGYABBV
Forward yield31.40%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$143.4K$102.3K
Annual income after 10y$19,741.77$24,771.77
Total dividends collected$99.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PCTGY vs ABBV ($10,000, DRIP)

YearPCTGY PortfolioPCTGY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,840$3,139.72$11,550$430.00+$2.3KPCTGY
2$18,870$4,061.01$13,472$627.96+$5.4KPCTGY
3$25,365$5,174.68$15,906$926.08+$9.5KPCTGY
4$33,642$6,500.92$19,071$1,382.55+$14.6KPCTGY
5$44,055$8,058.07$23,302$2,095.81+$20.8KPCTGY
6$57,000$9,861.93$29,150$3,237.93+$27.9KPCTGY
7$72,915$11,925.17$37,536$5,121.41+$35.4KPCTGY
8$92,276$14,256.85$50,079$8,338.38+$42.2KPCTGY
9$115,598$16,862.07$69,753$14,065.80+$45.8KPCTGY
10$143,431$19,741.77$102,337$24,771.77+$41.1KPCTGY

PCTGY vs ABBV: Complete Analysis 2026

PCTGYStock

Pact Group Holdings Ltd engages in the manufacture and supply of rigid plastic and metal packaging in Australia, New Zealand, Asia, and internationally. The company operates through Packaging and Sustainability, Materials Handling and Pooling, and Contract Manufacturing Services segments. It offers packaging products for dairy and beverage, processed food, health and personal care, fresh food, household and industrial, and closures industries; reusable products, such as garment hangers, fresh produce crates, IBC's, and steel drums for supply chain, environmental, infrastructure, and retail accessories applications. The company recycles post-consumer and post-industrial polyethylene terephathale products comprising water and soft drink bottles, bakery trays, and protein trays into recycled food-grade resins; recycles post-consumer and post-industrial high-density polyethylene products consisting of milk, laundry, and shampoo bottles into recycled resin to manufacture milk and dairy containers, personal and homecare bottles, lubricant containers, pipe, and mobile garbage bins. In addition, it recycles post-consumer and post-industrial polypropylene products that include ice cream tubs, yoghurt containers, shopping, and produce crates into recycled resin to manufacture plant pots, paint pails, bread, milk, produce crates, and bins; and recycles pallet, shrink wrap, and shopping bags to manufacture builders' film, silage wrap, dampcourse, garage bags, and other sheet products. Further, the company offers contract manufacturing services for homecare, personal care, cosmetics, automotive, promotional packaging, aerosol and liquid based consumer products, and pharmaceutical and nutraceutical manufacturing services, as well as provides packaging service for coated and uncoated tables, capsules, and powdered products. Pact Group Holdings Ltd was founded in 2002 and is headquartered in Cremorne, Australia.

Full PCTGY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PCTGY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCTGY vs SCHDPCTGY vs JEPIPCTGY vs OPCTGY vs KOPCTGY vs MAINPCTGY vs JNJPCTGY vs MRKPCTGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.